EU grant funding
Receives grant funding for the following activity(ies):
Project Description
Sabiad is developing an innovative Biotech platform to easily distinguish infections caused by Staphylococcus Aureus (SA) from natural responses of the body to a foreign material (inflammation) using a fully human monoclonal antibody (1D9) binding with high affinity to staphylococci.
Since SA is the major causative agent of implant-associated infections, the first application of this technology is the fast and accurate diagnosis of suspected SA-related infections after replacement of arthritic or dysfunctional hips or knees by prosthetics. Initial market research and inputs from leading orthopedic surgeons have validated the benefit of this technology in hip/knee revision surgery.
This project aims to progress on the clinical, technical, and economic feasibility of Sabiad’s contrast agent for detection of SA-related infection in orthopedic surgery, establishing Sabiad’s proof-of-concept, by developing the antibody (and its safety documentation) for use in a first-in-human clinical study to be executed at and by the UMCG (University Medical Center Groningen).
